Healthcare
Live Price
Offline$57.94
+5.35% today
Window Change
+12.11%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bio-Techne Corporation (TECH) is a Healthcare stock with a market cap of $8.61B and listed on NASDAQ. The stock last traded around $57.94 and up 12.1% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of -56.1%, a dividend yield of 0.6%. What stands out right now is revenue +5.2%, EPS -56.1%, free cash flow +8.7% with operating margin 9.6% and ROIC 3.5%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 105.7 and price/sales 7.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TECH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TECH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TECH Max Drawdown
-3.70%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TECH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$931.0M
-15.8% YoY
FY Net Income
$140.4M
-48.4% YoY
Free Cash Flow
$307.9M
+9.8% YoY
Revenue Growth
+5.2%
EPS Growth
-56.1%
Gross Margin
65.2%
Net Margin
6.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.1B | 1.1B | 931M |
| Gross Profit | 790M | 770M | 770M | 756M | 633M |
| Operating Income | 102M | 207M | 299M | 297M | 237M |
| EBITDA | 217M | 313M | 457M | 414M | 250M |
| Net Income | 73M | 168M | 285M | 272M | 140M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 162M | 152M | 181M | 173M | 199M |
| Total Assets | 2.6B | 2.7B | 2.6B | 2.3B | 2.3B |
| Total Liabilities | 639M | 635M | 672M | 594M | 692M |
| Shareholder Equity | 1.9B | 2.1B | 2.0B | 1.7B | 1.6B |
| Total Debt | 444M | 420M | 455M | 326M | 421M |
| Net Debt | 282M | 268M | 274M | 153M | 221M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
352M
+8.3% YoY
Capital Expenditures
44M
+1.4% YoY
Free Cash Flow
308M
+9.8% YoY
Key ratios
Gross Margin
65.2%
Operating Margin
9.6%
Net Margin
6.7%
ROE
4.1%
Debt / Equity
0.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.